Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis [3]

Diabetes Care

Volumn 30, Issue 5, 2007, Pages

  Targher, Giovanni ^a,b   Bertolini, Lorenzo ^a   Scala, Luca ^a   Zenari, Luciano ^a   Lippi, Giuseppe ^b   Franchini, Massimo ^c   Arcaro, Guido ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c Civil Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; FIBRINOLYSIS; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LETTER; LIVER BIOPSY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL;

BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

EID: 34247610903     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0109     Document Type: Letter

References (13)

1. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G: Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54:3541-3546, 2005
2. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, Falezza G: Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 23:403-409, 2006
3. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212-1218, 2007
4. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M: Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 191:391-396, 2007
5. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP: Elevated serum alanine aminotrasferase activity and calculated risk of coronary heart disease in the United States. Hepatology 43:1145-1151, 2006
6. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873, 2006
7. Targher G, Bertolini L, Padovani R, Rodella S, Zoppini G, Zenari L, Cigolini M, Falezza G, Arcaro G: Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29:1325-1330, 2006
8. Targher G: Mini-review: Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 24:1-6, 2007
9. Vaughan DE: PAI-1 and athero-thrombosis. J Thromb Haemost 3:1879-1883, 2005
10. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467-2474, 1999
11. Alessi MC, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-Vague I: Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 23:1262-1268, 2003
12. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G: Liver steatosis and its relation to plasma haemostatic factors in apparently healthy males: role of the metabolic syndrome. Thromb Haemostas 76:69-73, 1996
13. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G: Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in nondiabetic men: role of visceral adipose tissue. Diabet Med 22:1354-1358, 2005